Ascent Changes to Anchor

3/30/10

Ascent Therapeutics, a Cambridge, MA-based pre-clinical stage drug development company, announced today that it has changed its name to Anchor Therapeutics to better reflect its technology. The company is developing drugs based on “pepducins,” which anchor in cell membranes to target molecules called G protein coupled receptors that are involved in ailments such as cancers, heart disease, inflammation, pain, and metabolic disorders. Anchor’s backers include HealthCare Ventures, Novartis Option Fund, and TVM Capital.

By posting a comment, you agree to our terms and conditions.